EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

Meletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, Sosana Delimpasi, Vladimir Vorobyev, Hang Quach, Ivan Spicka, Jakub Radocha, Pawel Robak, Kihyun Kim, Michele Cavo, Kazuhito Suzuki und 11 weitere

New England Journal of Medicine · 2024-08 · 391 (5) · 408-421

DOI: 10.1056/nejmoa2403407 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, 2024-08. Verfasst von Meletios Athanasios Dimopoulos und 22 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens (M.A.D.), and General Hospital Evang…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Multiple Myeloma. Die Arbeit wurde bisher 197-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneMultiple MyelomaProgression-Free SurvivalThalidomideAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedBortezomibKaplan-Meier EstimateLenalidomideRecurrenceTreatment OutcomeNeoplasm Recurrence, LocalDrug Resistance, NeoplasmDisease ProgressionEye Diseases

Substanzen

Antibodies, Monoclonal, Humanizedbelantamab mafodotinBortezomibDexamethasoneLenalidomidepomalidomideThalidomide

Autor:innen und Institutionen

  • From the Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens (M.A.D.), and General Hospital Evangelismos (S.D.) - both in Athens; the Department of Hematology, Ankara…

Förderung

  • GlaxoSmithKline

Zitieren

APA

Dimopoulos, M. A., Beksac, M., Pour, L., Delimpasi, S., Vorobyev, V., Quach, H., Spicka, I., Radocha, J., Robak, P., Kim, K., Cavo, M., Suzuki, K., Morris, K., Pompilus, F., Phillips-Jones, A., Zhou, X. L., Fulci, G., Sule, N., Kremer, B. E., …, & DREAMM-8 Investigators (2024). Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. New England Journal of Medicine, 391(5), 408-421. https://doi.org/10.1056/nejmoa2403407

Vancouver

Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. New England Journal of Medicine. 2024;391(5):408-421. doi:10.1056/nejmoa2403407

BibTeX
@article{Dimopoulos2024,
  author = {Dimopoulos, Meletios Athanasios and Beksac, Meral and Pour, Ludek and Delimpasi, Sosana and Vorobyev, Vladimir and Quach, Hang and Spicka, Ivan and Radocha, Jakub and Robak, Pawel and Kim, Kihyun and Cavo, Michele and Suzuki, Kazuhito and Morris, Kristin and Pompilus, Farrah and Phillips-Jones, Amy and Zhou, Xiaoou L and Fulci, Giulia and Sule, Neal and Kremer, Brandon E and Opalinska, Joanna and Mateos, María-Victoria and Trudel, Suzanne and DREAMM-8 Investigators, DREAMM-8 Investigators},
  title = {Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {5},
  pages = {408--421},
  doi = {10.1056/nejmoa2403407}
}
Kostenlos starten →